Sun Pharmaceutical Industries Ltd 2022 AR2
The report highlights Sun Pharmaceutical Industries Limited's performance for the fiscal year 2021-22, during which it became the first Indian pharmaceutical company to cross US$ 5 billion in global revenues. The company expanded its global specialty business, which contributed approximately 13% to consolidated revenues, driven by strong sales of Ilumya, Cequa, and Odomzo. Sun Pharma also voluntarily adopted the Business Responsibility and Sustainability Report (BRSR) framework, committing to reduce carbon emissions by 35% by 2030 and water consumption by 10% by 2025.
Company: Sun Pharmaceutical Industries Ltd
Sector: Manufacturing
Country: India
Year: 2022
Type: AR2
Pages: 324
Back to company
Sun Pharmaceutical Industries Ltd
Annual Report
The report highlights Sun Pharmaceutical Industries Limited's performance for the fiscal year 2021-22, during which it became the first Indian pharmaceutical company to cross US$ 5 billion in global revenues. The company expanded its global specialty business, which contributed approximately 13% to consolidated revenues, driven by strong sales of Ilumya, Cequa, and Odomzo. Sun Pharma also voluntarily adopted the Business Responsibility and Sustainability Report (BRSR) framework, committing to reduce carbon emissions by 35% by 2030 and water consumption by 10% by 2025.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Apr 1, 2021 - Mar 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees